Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.

doi:10.1016/j.bmcl.2008.05.024

Paper

Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.

Published Jun 15, 2008 · Guozhang Xu, L. L. Searle, T. V. Hughes

Bioorganic & medicinal chemistry letters

Q2 SJR score

47

Citations

1

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Study Snapshot

Novel 4-aminopyrimidine-5-carbaldehyde oximes are potent and selective inhibitors of both EGFR and ErbB-2 tyrosine kinases, with nanomolar IC 50 values.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.

References

Citations